Misplaced Pages

Otlertuzumab (TRU‐016) is a humanized monoclonal antibody that targets CD37 designed for the treatment of cancer.

This drug was developed by Emergent BioSolutions and has been in clinical trials for lymphoma and Chronic Lymphocytic Leukemia (CLL)

References

1. Payandeh Z, Noori E, Khalesi B, Mard-Soltani M, Abdolalizadeh J, Khalili S (December 2018). "Anti-CD37 targeted immunotherapy of B-Cell malignancies". Biotechnology Letters. 40 (11–12): 1459–1466. doi:10.1007/s10529-018-2612-6. PMID 30293139. S2CID 52925605.
2. "Otlertuzumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
3. "Otlertuzumab". ClinicalTrails.gov. U.S. National Library of Medicine.

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Monoclonal antibody stubs
• Monoclonal antibodies